Home›Trial›NCT07323654
🔬NCT07323654Phase 2RECRUITING

A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma

Study Summary

This Phase 2b study is designed to evaluate the safety and efficacy of KT-621 in participants with uncontrolled moderate to severe eosinophilic asthma. The main goals of this study are to investigate how effective KT-621 is at treating uncontrolled moderate to severe eosinophilic asthma, the safety and tolerability of KT-621, and how KT-621 behaves in the body.

Conditions
Eosinophilic Asthma
Interventions / Drugs
KT-621Placebo
View on ClinicalTrials.gov ↗
Sponsor
KYMR
Kymera Therapeutics
Protein Degradation
D38/100
Study Details
Enrollment264 participants
Primary Completion—
Lead SponsorKymera Therapeutics, Inc.
Data Retrieved2026-04-11 04:19:13.712932+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.